Epoch Biodesign

Epoch BiodesignEpoch Biodesign
Epoch Biodesign

Epoch Biodesign

Epoch Biodesign uses enzymes to break down plastic waste into monomers for new plastic production.

Website
2021Active
Rate
Advertise here

About

Epoch Biodesign is a biotechnology company focused on developing enzymatic solutions for plastic recycling. Their technology utilizes engineered enzymes to depolymerize plastic waste into its constituent monomers, which can then be used to create virgin-quality new plastics. This approach offers a more sustainable and circular method for managing plastic waste compared to traditional recycling or disposal methods.

Technology stack

detected 2026-07-04
CDN
Cloudflare
EmailGoogle Workspace
Stack
Webflow
Video
Vimeo
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Epoch Biodesign do?

Epoch Biodesign is a biotechnology company focused on developing enzymatic solutions for plastic recycling. Their technology utilizes engineered enzymes to depolymerize plastic waste into its constituent monomers, which can then be used to create virgin-quality new plastics. This approach offers a more sustainable and circular method for managing plastic waste compared to traditional recycling or disposal methods.

How much funding has Epoch Biodesign raised?

Epoch Biodesign has raised a total of $12M in funding. The most recent round on record is Funding Round.

Where is Epoch Biodesign headquartered?

Epoch Biodesign is headquartered in Cambridge, Massachusetts, United States.

When was Epoch Biodesign founded?

Epoch Biodesign was founded in 2021.

What industry does Epoch Biodesign operate in?

Epoch Biodesign operates in Biotechnology, Chemicals, Sustainability, Circular Economy, Waste Management.

What is Epoch Biodesign's revenue?

StartupHub estimates Epoch Biodesign's annual revenue at $80.3M (range $37.9M to $136.2M, 44% confidence), based on comparable companies in the sector.

What is Epoch Biodesign's valuation?

StartupHub estimates Epoch Biodesign's effective valuation at $1.1B (range $735.6M to $1.4B, 42% confidence), based on comparable companies in the sector.